Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine whether the presence of circulating/disseminated tumour cells (CTCs/DTCs) in the blood and bone marrow of the resectable lung cancer (NSCLC) patients is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Device for CTC/DTC detection | Diagnostic Test | The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples. |
| Measure | Description | Time Frame |
|---|---|---|
| CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells in lung cancer patients | The absolute gene expression of CEA, EGFR, LunX, c-met and EpCAM mRNA positive circulating tumour cells(CTCs) isolated from peripheral blood, tumour draining blood and bone marrow samples of lung cancer patients will be measured using real-time RT-PCR method. The gene expression will be normalized per microgram of total mRNA. | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Cancer specific survival in CTC positive NSCLC patients | The cancer specific survival, overall survival and disease free survival will be measured from the time of diagnosis to the time of event. Two groups of patients will be compared: A: Patients with the presence of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure. B: Patients with the absence e of CTCs in peripheral blood, tumour draining blood and bone marrow before NSCLC surgery as described in primary outcome measure. |
Not provided
Inclusion Criteria:
Non-small cell lung cancer, non-metastatic
Exclusion Criteria:
Prior neoadjuvant chemoradiotherapy Prior lung cancer Cancer duplicity
Not provided
Not provided
Not provided
Patients with confirmed non-metastatic NSCLC undergoing radical surgery with curative intent.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marian Hajduch, MD, PhD | Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Olomouc | Olomouc | Česká Republika | 77900 | Czechia |
The anonymized metadata will be publicly available after publishing the results.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D009360 | Neoplastic Cells, Circulating |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
ctDNA from plasma blood samples. DNA and RNA from nucleated blood cells. DNA and RNA from tumour tissue.
| 5 years |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D009362 | Neoplasm Metastasis |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |